Peng-Xiang Zhang1, Lin Zeng1, Lu Meng1, Hui-Lin Li2, Heng-Xia Zhao3, De-Liang Liu4. 1. The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, People's Republic of China. 2. Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, People's Republic of China. 3. Endocrinology Department of Shenzhen Traditional Chinese Medicine Hospital, No. 1 Fuhua Road, Shenzhen, 518033, Guangdong Province, People's Republic of China. 4. Endocrinology Department of Shenzhen Traditional Chinese Medicine Hospital, No. 1 Fuhua Road, Shenzhen, 518033, Guangdong Province, People's Republic of China. ldl2580@gzucm.edu.cn.
Abstract
BACKGROUND: Prediabetes is a hypermetabolic syndrome with blood sugar levels falling between the normal and diabetes. People with prediabetes have a significantly increased chances of developing diabetes, cardiovascular and cerebrovascular diseases, tumors, dementia, and other diseases in the future when compared to the healthy population. However, prediabetes is mainly treated based on lifestyle intervention, currently without targeted drug treatment plan. Traditional Chinese medicine (TCM), which has a longstanding experience, has been shown in clinical studies to be effective for the treatment of diabetes and its related complications. Furthermore, different dosage forms such as decoction and granule have developed gradually in clinical application. Preliminary studies have found that Huoxue-Jangtang Decoction (HJD), with good hypoglycemic and lipid-regulating effects, is potentially one of the complementary and alternative treatments for prediabetes. Therefore, this project intends to perform a prospective clinical study to observe the clinical effectiveness of HJD on prediabetes and the consistency of the efficacy of formula granules and the elixation. METHODS: This is a prospective, randomized, double-blind, and placebo-controlled clinical trial. A total of 183 participants are randomly assigned to HJD Formula Granules plus lifestyle intervention, HJD Elixation plus lifestyle intervention, and placebo plus lifestyle intervention. All subjects undergo 1 day of screening before participating in the study, followed by 84 days of drug intervention and observation. During and after treatment, the main outcome measures include fasting blood glucose and 2-hour postprandial blood glucose. DISCUSSION: This research attempts to verify the clinical efficacy and possible mechanism of HJD in the treatment of prediabetes, and prove the consistency of HJD Formula Granules with HJD Elixation. This study also aims to provide a treatment that is both effective and safe for prediabetic patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: ChiCTR2200060813, Registered 12 June 2022.
BACKGROUND: Prediabetes is a hypermetabolic syndrome with blood sugar levels falling between the normal and diabetes. People with prediabetes have a significantly increased chances of developing diabetes, cardiovascular and cerebrovascular diseases, tumors, dementia, and other diseases in the future when compared to the healthy population. However, prediabetes is mainly treated based on lifestyle intervention, currently without targeted drug treatment plan. Traditional Chinese medicine (TCM), which has a longstanding experience, has been shown in clinical studies to be effective for the treatment of diabetes and its related complications. Furthermore, different dosage forms such as decoction and granule have developed gradually in clinical application. Preliminary studies have found that Huoxue-Jangtang Decoction (HJD), with good hypoglycemic and lipid-regulating effects, is potentially one of the complementary and alternative treatments for prediabetes. Therefore, this project intends to perform a prospective clinical study to observe the clinical effectiveness of HJD on prediabetes and the consistency of the efficacy of formula granules and the elixation. METHODS: This is a prospective, randomized, double-blind, and placebo-controlled clinical trial. A total of 183 participants are randomly assigned to HJD Formula Granules plus lifestyle intervention, HJD Elixation plus lifestyle intervention, and placebo plus lifestyle intervention. All subjects undergo 1 day of screening before participating in the study, followed by 84 days of drug intervention and observation. During and after treatment, the main outcome measures include fasting blood glucose and 2-hour postprandial blood glucose. DISCUSSION: This research attempts to verify the clinical efficacy and possible mechanism of HJD in the treatment of prediabetes, and prove the consistency of HJD Formula Granules with HJD Elixation. This study also aims to provide a treatment that is both effective and safe for prediabetic patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: ChiCTR2200060813, Registered 12 June 2022.
Authors: Amr T M Saeb; Khalid A Al-Rubeaan; Khalid Aldosary; G K Udaya Raja; Balavenkatesh Mani; Mohamed Abouelhoda; Hamsa T Tayeb Journal: Microb Pathog Date: 2019-01-06 Impact factor: 3.738
Authors: Jaana M Heinze; Andrew Costanzo; Inga Baselier; Andreas Fritsche; Sabine Frank-Podlech; Russell Keast Journal: Appetite Date: 2017-12-05 Impact factor: 3.868
Authors: Christopher N Ford; Mary Beth Weber; Lisa R Staimez; Ranjit M Anjana; Karthikeyan Lakshmi; Viswanathan Mohan; K M Venkat Narayan; Ranjani Harish Journal: Acta Diabetol Date: 2018-11-13 Impact factor: 4.280
Authors: Andreas Fritsche; Robert Wagner; Martin Heni; Kostantinos Kantartzis; Jürgen Machann; Fritz Schick; Rainer Lehmann; Andreas Peter; Corinna Dannecker; Louise Fritsche; Vera Valenta; Renate Schick; Peter Paul Nawroth; Stefan Kopf; Andreas F H Pfeiffer; Stefan Kabisch; Ulrike Dambeck; Michael Stumvoll; Matthias Blüher; Andreas L Birkenfeld; Peter Schwarz; Hans Hauner; Julia Clavel; Jochen Seißler; Andreas Lechner; Karsten Müssig; Katharina Weber; Michael Laxy; Stefan Bornstein; Annette Schürmann; Michael Roden; Martin Hrabe de Angelis; Norbert Stefan; Hans-Ulrich Häring Journal: Diabetes Date: 2021-09-16 Impact factor: 9.461